<DOC>
	<DOCNO>NCT01546649</DOCNO>
	<brief_summary>Hormone dynamic , pharmacokinetics , safety , efficacy TAP-144-SR ( 6M ) evaluate TAP-144-SR ( 3M ) postoperative hormone therapy-naïve patient premenopausal breast cancer</brief_summary>
	<brief_title>A Phase 3 Comparative Study TAP-144-SR ( 6M ) Postoperative Hormone Therapy-naïve Patients With Premenopausal Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . The participant histopathologicallyconfirmed primary breast cancer Japanese . 2 . The participant age 20 year old informed consent obtain 3 . The participant estrogen receptor ( ER ) positive tumor cell and/or progesterone receptor ( PgR ) positive primary tumor . And HER2 negative . 4 . The participant breast cancer clinical stage T1T3 , Nany M0 TNM classification ( seventh edition , propose UICC 2009 ) . ( No distant metastasis lung , liver bone confirm imagebased diagnosis study enrollment . The image take within 12 week prior study enrollment also available diagnosis . ) The number axillary lymph node metastasis limit . 5 . Any operative procedure breast cancer acceptable . In principle , breastconserving surgery , participant receive postoperative radiation conserve breast . 6 . Neoadjuvant chemotherapy adjuvant chemotherapy prior study enrollment acceptable . ( It advisable kind chemotherapy perform site . ) 7 . The participant history regular menstrual period within 12 week prior study enrollment , participant FSH le 40 mIU/mL E2 10 pg/mL measure within 12 week prior study enrollment . The participant chemical menopause ( i.e. , FSH le 40 mIU/mL E2 10 pg/mL ) within 12 week complete adjuvant chemotherapy . 8 . The participant condition receive study drug Tamoxifen ( TAM ) within 12 week surgery adjuvant chemotherapy prior study enrollment . Adjuvant chemotherapy prior study require complete time study enrollment . 9 . The participant ECOG performance status grade 0 1 time study enrollment . 10 . The participant meet follow criterion hepatic , renal bone marrow function laboratory test result screen : Hepatic function : AST ( GOT ) ≤ 3.0 time upper limit normal ( ULN ) ALT ( GPT ) ≤ 3.0 time ULN Renal function : serum creatinine level &lt; 1.5 time ULN Bone marrow function : white blood cell count ≥ 3,000/mm3 platelet count ≥ 100,000/μL hemoglobin ≥ 10.0g/dL 11 . The participant agree use nonhormonal method contraception study period . 1 . The participant receive neoadjuvant adjuvant hormonal therapy late breast cancer surgery . 2 . The participant receive bilateral oophorectomy bilateral ovarian irradiation . 3 . The participant inflammatory breast cancer bilateral breast cancer . 4 . The participant noninvasive ductal carcinoma . 5 . The participant multiple primary cancer , history carcinoma organ . 6 . The participant pregnant breastfeeding . 7 . The participant history hypersensitivity synthetic LHRH , LHRH derivative , TAM , TAM analogue ( antiestrogen ) component study drug . 8 . The participant history , diagnose thromboembolism include myocardial infarction , cerebral infarction , venous thrombosis , pulmonary embolism , cardiac failure . 9 . Patients whose QTcF interval exceed 460 msec 12lead electrocardiogram screening .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>